首页|ICU患者多黏菌素B血药浓度及不良反应分析

ICU患者多黏菌素B血药浓度及不良反应分析

扫码查看
目的 探讨重症监护室(ICU)患者多黏菌素B血药浓度达标情况及不良反应,为临床合理用药提供参考。方法 回顾性分析 61 例ICU患者使用多黏菌素B治疗后的稳态 24h浓度-时间曲线下面积(AUCss,24h)达标情况、影响因素及不良反应。结果 61 例患者多黏菌素B AUCss,24h达标率为 37。70%(23/61)。肌酐清除率与谷浓度(Cmin)及AUCss,24h差异有统计学意义(P<0。05),肌酐清除率与Cmin(r=-0。45)及AUCss,24h均为负相关(r=-0。34)。单因素和多因素分析显示,AUCss,24h与滴注时间显著相关(P<0。05),输注时间>1 小时组AUCss,24h达标率高于 1 小时组。虽然AUCss,24h与年龄及肾功能差异无统计学意义(P>0。05),但是年龄增大或中重度肾功能不全,AUCss,24h达标率降低。多黏菌素B相关肾损伤发生率为 45。24%(19/42),肾损伤组AUCss,24h>100(mg·h)/L比例较高。结论 多黏菌素B AUCss,24h可能与年龄、输注时间及肾功能有关,多黏菌素B相关肾损伤与AUCss,24h>100(mg·h)/L有关,临床需根据患者情况进行血药浓度监测和个体化给药。
Analysis of Polymyxin B Blood Concentration and Adverse Reactions in ICU Patients
Objective To explore the blood concentration of polymyxins B and its adverse reactions in ICU patients in order to provide references for rational drug use in clinic.Methods This was a retrospective study.AUCss,24h influencing factors and nephrotoxicity were studied in 61 ICU patients who received polymyxins B treatment.Results The compliance rate of polymyxins B AUCss,24h was 37.70%(23/61).There were significant differences between creatinine clearance and Cmin and AUCss,24h(P<0.05),and there were negative correlations between creatinine clearance and Cmin(r=-0.45)and AUCss,24h(r=-0.34).Univariate and multivariate analysis showed that AUCss,24h were significantly correlated with infusion time(P<0.05),and the standard reaching rate of AUCss,24h in the infusion time>1 hour group was higher than that in the 1 hour group.Although AUCss,24h had no significant correlation with age and renal function(P>0.05),with increasing age or moderate and severe renal insufficiency,the rate of reaching the standard of AUCss,24h decreased.The incidence of polymyxins B related renal injury was 45.24%(19/42),and the proportion of AUCss,24h>100(mg·h)/L was higher in the renal injury group.Conclusion Polymyxins B AUCss,24h may be related to age,infusion time and renal function.Polymyxins B associated renal injury was associated with AUCss,24h>100(mg·h)/L.Monitoring of blood concentration and individualized administration should be carried out according to patients'conditions.

Polymyxins BTherapeutic drug monitoringBlood drug concentrationAdverse reaction

宋小玲、肖雄、吕燕妮、万青、钟海利、王燕霞

展开 >

南昌大学第一附属医院,江西 南昌 330038

南昌大学第四附属医院,江西 南昌 330002

多黏菌素B 治疗药物监测 血药浓度 不良反应

2024

药品评价
江西省药学会

药品评价

影响因子:0.672
ISSN:1672-2809
年,卷(期):2024.21(3)